Abstract:Myeloproliferative neoplasms (MPN) have an inherent tendency to evolve to the blast phase (BP), characterized by ≥20% myeloblasts in the blood or bone marrow. MPN-BP portends a dismal prognosis and currently, effective treatment modalities are scarce, except for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in selected patients, particularly those who achieve complete/partial remission. The mutational landscape of MPN-BP differs from de novo acute myeloid leukemia (AML) in several key aspects, such as significantly lower frequencies of FLT3 and DNMT3A mutations, and higher incidence of IDH1/2 and TP53 in MPN-BP. Herein, we comprehensively review the impact of the three signaling driver mutations (JAK2 V617F, CALR exon 9 indels, MPL W515K/L) that constitutively activate the JAK/STAT pathway, and of the other somatic non-driver mutations (epigenetic, mRNA splicing, transcriptional regulators, and mutations in signal transduction genes) that cooperatively or independently promote MPN progression and leukemic transformation. The MPN subtype, harboring two or more high-molecular risk (HMR) mutations (epigenetic regulators and mRNA splicing factors) and "triple-negative" PMF are among the critical factors that increase risk of leukemic transformation and shorten survival. Primary myelofibrosis (PMF) is the most aggressive MPN; and polycythemia vera (PV) and essential thrombocythemia (ET) are relatively indolent subtypes. In PV and ET, mutations in splicing factor genes are associated with progression to myelofibrosis (MF), and in ET, TP53 mutations predict risk for leukemic transformation. The advent of targeted next-generation sequencing and improved prognostic scoring systems for PMF inform decisions regarding allo-HSCT. The emergence of treatments targeting mutant enzymes (e.g., IDH1/2 inhibitors) or epigenetic pathways (BET and LSD1 inhibitors) along with new insights into the mechanisms of leukemogenesis will hopefully lead the way to superior management strategies and outcomes of MPN-BP patients.

Current myeloproliferative neoplasm scoring systems for clinical practice

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms

Advances in understanding and management of myeloproliferative neoplasms

Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN

Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)

Characterization of myeloproliferative neoplasms based on genetics only and prognostication of transformation to blast phase

Pathogenesis and management of high molecular risk myeloproliferative neoplasms

Myeloproliferative neoplasms: young patients, current data and future considerations

Advances in molecular evaluation of myeloproliferative neoplasms

[Research Progress of Myeloproliferative Neoplasms].

Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study

Oncogenes in myeloproliferative disorders

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics

New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?

Cytogenetics and genomics in CML and other myeloproliferative neoplasms

Experimental therapeutics for patients with myeloproliferative neoplasias

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms

Recent advances in understanding myelofibrosis and essential thrombocythemia

Development of Pathogenesis and Therapeutics in Myeloproliferative Neoplasms

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms